Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 1:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 1,804 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabetes Mellitus - Type 1 Clear all
Completed Not applicable Interventional Results available

Two Way Crossover Closed Loop MPC vs Control IQ

NCT05799781
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
MPC closed-loop system, t:slim X2 pump with Dexcom G6 CGM and Control IQ
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 17, 2026, 1:08 PM EDT
Withdrawn Not applicable Interventional

Use of the Insulin Pump in Cystic Fibrosis Patients With Impaired Glucose Tolerance or CFRD and in Type 1 Diabetes Patients.

NCT00287456
View directory record Official record
Conditions
Cystic Fibrosis Related Diabetes
Interventions
Insulin Pump, Insulin, Oral Glucose Tolerance Test, Whole body Protein Turnover
Device · Drug · Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
12 Years to 32 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Oct 17, 2026, 1:08 PM EDT
Completed No phase listed Observational

Management of Type 1 Diabetes Among Adolescents

NCT00340639
View directory record Official record
Conditions
Type I Diabetes
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
7 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 17, 2026, 1:08 PM EDT
Completed Phase 2 Interventional Results available

A Study for Patients With Type 1 Diabetes

NCT01049412
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
LY2605541, Insulin glargine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
10
States / cities
Chula Vista, California • Atlanta, Georgia • Idaho Falls, Idaho + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 17, 2026, 1:08 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Imatinib Treatment in Recent Onset Type 1 Diabetes Mellitus

NCT01781975
View directory record Official record
Conditions
Diabetes Mellitus, Type I, Diabetes Mellitus, Insulin-Dependent, 1, Type 1 Diabetes Mellitus, Insulin-Dependent Diabetes Mellitus 1, IDDM
Interventions
Imatinib Mesylate, Placebo (For imatinib mesylate)
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 45 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
8
States / cities
San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Oct 17, 2026, 1:08 PM EDT
Recruiting Phase 3 Interventional

Clinical Application of Stem Cell Educator Therapy in Type 1 Diabetes

NCT04011020
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Stem Cell Educator therapy
Combination Product
Lead sponsor
Throne Biotechnologies Inc.
Industry
Eligibility
10 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 17, 2026, 1:08 PM EDT
Recruiting Phase 3 Interventional

A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 Diabetes

NCT04786262
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Impaired Hypoglycemic Awareness, Severe Hypoglycemia
Interventions
VX-880, VX-017
Biological
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
12
States / cities
Duarte, California • San Francisco, California • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 17, 2026, 1:08 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Equivalence of A Stable Liquid Glucagon Formulation With Freshly Reconstituted Lyophilized Glucagon

NCT02018627
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Xeris glucagon, Lilly glucagon
Drug
Lead sponsor
Steven J. Russell, MD, PhD
Other
Eligibility
21 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Oct 17, 2026, 1:08 PM EDT
Completed Phase 2 Interventional Results available

Research Study to Look at Fast-acting Insulin Aspart With the Insulin Pump System 'iLet™' in Adults With Type 1 Diabetes

NCT03816761
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Fast-acting insulin aspart, iLet™
Drug · Device
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 11, 2020 · Synced Oct 17, 2026, 1:08 PM EDT
Completed Phase 1Phase 2 Interventional

Pancreatic Islets and Parathyroid Gland Co-transplantation for Treatment of Type 1 Diabetes

NCT03977662
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Co-transplantation of PTG with pancreatic islets
Combination Product
Lead sponsor
Peter Stock
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 17, 2026, 1:08 PM EDT
Active, not recruiting Not applicable Interventional

Multi-Site Eating Disorder Prevention Program for Type 1 Diabetes

NCT05399446
View directory record Official record
Conditions
Type 1 Diabetes, Eating Disorders
Interventions
Diabetes Body Project, Educational Group
Behavioral
Lead sponsor
Oslo University Hospital
Other
Eligibility
14 Years to 35 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Stanford, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 4, 2024 · Synced Oct 17, 2026, 1:08 PM EDT
Active, not recruiting Phase 2 Interventional

Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule

NCT06812988
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Brivekimig, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years to 35 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Atlanta, Georgia • Columbus, Georgia • Farmington Hills, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 17, 2026, 1:08 PM EDT
Completed Not applicable Interventional Results available

Early Feasibility Study 2 of Outpatient Control-to-Range - Testing System Efficacy

NCT01714505
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Diabetes Assistant (DiAs)
Device
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 64 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Santa Barbara, California • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 9, 2014 · Synced Oct 17, 2026, 1:08 PM EDT
Completed Phase 1 Interventional

Bigfoot Biomedical Clinical Research Center (CRC) Trial

NCT02849288
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Bigfoot Biomedical Type 1 Diabetes Management System (T1DMS)
Device
Lead sponsor
Bigfoot Biomedical Inc.
Industry
Eligibility
7 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
3
States / cities
Santa Barbara, California • Stanford, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 19, 2016 · Synced Oct 17, 2026, 1:08 PM EDT
Active, not recruiting Phase 2 Interventional

TArgeting Type 1 Diabetes Using POLyamines (TADPOL)

NCT05594563
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
DFMO, Placebo
Drug
Lead sponsor
Emily K. Sims
Other
Eligibility
4 Years to 40 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Aurora, Colorado • Chicago, Illinois • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 17, 2026, 1:08 PM EDT
Recruiting Not applicable Interventional

Gemini Study: A Prospective, Multicenter Evaluation of Performance and Safety of the Eversense Gemini System With Flash Glucose Measurement Feature

NCT07386340
View directory record Official record
Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Continuous Glucose Monitoring System
Device
Lead sponsor
Senseonics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Escondido, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 17, 2026, 1:08 PM EDT
Completed Phase 4 Interventional

Adrenocorticotropic Hormone (ACTH) Treatment of Nephrotic Range Proteinuria in Diabetic Nephropathy (NRDN)

NCT01028287
View directory record Official record
Conditions
Diabetic Nephropathy, Nephrotic Syndrome
Interventions
ACTH
Drug
Lead sponsor
Southeast Renal Research Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated May 31, 2013 · Synced Oct 17, 2026, 1:08 PM EDT
Completed Not applicable Interventional Results available

Nurse Telephone Management of Cholesterol in Diabetes

NCT00950963
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
Phone Counseling, Standard Clinical Care
Behavioral · Other
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
17 Years and older
Enrollment
762 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Oct 17, 2026, 1:08 PM EDT
Terminated Phase 1 Interventional

Multiple Dose Escalation Trial Of PF-04603629 Given To Subjects With Type 2 Diabetes Mellitus

NCT00637338
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
PF-04603629, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
4
States / cities
Phoenix, Arizona • Miami, Florida • Wichita, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2009 · Synced Oct 17, 2026, 1:08 PM EDT
Completed Phase 1 Interventional Results available

A Pilot Study of Moderate Hyperbilirubinemia in Type 1 Diabetes Mellitus

NCT01421355
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Atazanavir
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 21, 2014 · Synced Oct 17, 2026, 1:08 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Role of Pregnancy Related Hormones in Lowering the Insulin Requirement in Pregnant Women With Type 1 Diabetes

NCT01265017
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Estradiol, medroxyprogesterone, hydrocortisone, GH, Matching placebo
Drug
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2020
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2018 · Synced Oct 17, 2026, 1:08 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy Alone

NCT02531035
View directory record Official record
Conditions
Type 1 Diabetes Mellitus (T1DM), High Level of Sugar (Glucose) in the Blood
Interventions
Sotagliflozin, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
33
States / cities
Concord, California • Escondido, California • La Jolla, California + 30 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Oct 17, 2026, 1:08 PM EDT
Completed Not applicable Interventional Results available

Cognitive Adaptations to Reduce Emotional Stress Associated With Type 1 Diabetes

NCT03698708
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
CARES Intervention
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
5 Years to 12 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 11, 2022 · Synced Oct 17, 2026, 1:08 PM EDT
Completed Not applicable Interventional Results available

Reduction of Nocturnal Hypoglycemia and Hyperglycemia in the Home Using Predictive Algorithms

NCT02438189
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Predictive Hyperglycemia Minimization Algorithm, Predictive Hypoglycemia Minimization Algorithm
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
15 Years to 45 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Stanford, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 17, 2026, 1:08 PM EDT